In vitro approaches revealed a selective toxicity in ABC-DLBCL cell lines with mutations in CD79A/CD79B and MYD88L265 [15,63], suggesting a potential targeted therapy for ABC-DLBCL or the newly proposed genetic subtype MCD-DLBCL. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.